Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33. ,Reck M, et al. KEYNOTE-024: 3-year survival update: Pembrolizumab versus platinum-based chemotherapy for advanced NSCLC. Abstract OA14.01. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Datopotamab deruxtecan bij gevorderde HR+/HER2- en tripelnegatieve borstkanker
jun 2024 | Borstkanker